Valeant Pharmaceuticals International, Inc.
Index- P/E108.09 EPS (ttm)1.48 Insider Own2.30% Shs Outstand334.60M Perf Week0.19%
Market Cap53.53B Forward P/E15.54 EPS next Y10.29 Insider Trans6.40% Shs Float325.85M Perf Month11.85%
Income502.40M PEG3.79 EPS next Q2.55 Inst Own66.80% Short Float2.03% Perf Quarter23.28%
Sales8.05B P/S6.65 EPS this Y-610.50% Inst Trans21.17% Short Ratio3.10 Perf Half Y36.27%
Book/sh15.27 P/B10.48 EPS next Y23.67% ROA1.80% Target Price52.38 Perf Year17.11%
Cash/sh2.42 P/C66.18 EPS next 5Y28.53% ROE9.80% 52W Range106.00 - 162.80 Perf YTD11.78%
Dividend- P/FCF39.75 EPS past 5Y-33.00% ROI-0.10% 52W High-1.74% Beta0.89
Dividend %- Quick Ratio1.10 Sales past 5Y50.10% Gross Margin70.20% 52W Low50.92% ATR3.41
Employees17200 Current Ratio1.40 Sales Q/Q33.40% Oper. Margin29.00% RSI (14)65.54 Volatility1.76% 2.20%
OptionableYes Debt/Eq3.18 EPS Q/Q127.70% Profit Margin6.20% Rel Volume0.66 Prev Close161.51
ShortableYes LT Debt/Eq3.04 Earnings- Payout0.00% Avg Volume2.13M Price159.97
Recom3.00 SMA203.75% SMA508.78% SMA20023.22% Volume1,409,782 Change-0.95%
Jan-09-15Reiterated UBS Buy $155 → $165
Feb-28-14Reiterated UBS Buy $141 → $170
Feb-28-14Reiterated RBC Capital Mkts Outperform $151 → $158
Feb-27-14Reiterated Aegis Capital Buy $160 → $180
Jan-08-14Reiterated UBS Buy $125 → $141
Jan-08-14Reiterated Ladenburg Thalmann Buy $123 → $155
Jan-08-14Reiterated FBR Capital Outperform $130 → $153
Dec-03-13Reiterated UBS Buy $115 → $125
Nov-01-13Reiterated Ladenburg Thalmann Buy $127 → $123
Oct-30-13Initiated FBR Capital Outperform $130
Oct-07-13Reiterated CRT Capital Buy $110 → $130
Aug-08-13Reiterated UBS Buy $96 → $115
Aug-07-13Reiterated Aegis Capital Buy $135 → $140
Jul-02-13Reiterated RBC Capital Mkts Outperform $76 → $100
Jun-10-13Upgrade CRT Capital Hold → Buy $100
May-29-13Reiterated Ladenburg Thalmann Buy $84 → $124
May-29-13Reiterated Deutsche Bank Buy $82 → $103
May-03-13Reiterated Deutsche Bank Buy $80 → $82
Apr-04-13Reiterated UBS Buy $83 → $81
Apr-04-13Reiterated RBC Capital Mkts Outperform $80 → $76
Jan-31-15 07:00AM  After Allergan loss, is Valeant dumpster diving? at Fortune
Jan-30-15 05:14PM  Valeant Pharmaceuticals International, Inc -- Moody's: Valeant's oncology foray credit positive but has execution risk at Moody's
05:02PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation EDGAR Online
11:39AM  Valeant Agrees To Buy Dendreon's Provenge at Investor's Business Daily
10:22AM  The Daily Docket: Trump Taj Mahal Workers Protest Outside Icahn's Office at The Wall Street Journal
09:39AM  Valeant Hopes To Buy Cancer Drug From Dendreon For $296M at
07:45AM  Activis CEO: Innovation vs. acquisition CNBC
06:01AM  Dendreon's Asset Rummage Sale Completes the Circle of Life at TheStreet
Jan-29-15 09:00PM  Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) PR Newswire
09:00PM  Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) CNW Group
Jan-28-15 08:02AM  Top Large-Cap Growth Stock Funds: Back On Their Feet at Investor's Business Daily
Jan-26-15 05:53PM  Large Medicals, Indian Stocks Rally To New Highs at Investor's Business Daily
10:41AM  Actavis Buys Auden Mckenzie, Now UK's Largest Generics Firm at
Jan-23-15 06:34PM  IBD 50 Turns In Solid Week As Market Uptrend Resumes at Investor's Business Daily
Jan-22-15 09:05PM  New Guru Jana Partners' Newest Stock Buys Gurufocus
Jan-21-15 05:35PM  Valeant's Bausch + Lomb Imaging System Cleared by FDA - Analyst Blog Zacks
12:23PM  Hungry Actavis pauses to digest Allergan at Financial Times
12:09PM  Valeant chief Pearson admits 'miscalculation' in Allergan pursuit at Financial Times
12:09PM  Actavis and Valeant raise prospect of more pharma deals at Financial Times
06:00AM  This Giant Drug Firm Won't Invent Medicines. Investors Are Cheering at Forbes
Jan-20-15 03:06PM  Salix Pharma Reportedly Exploring Sale; Stock Up at Investor's Business Daily
12:57PM  The Woman Who Is Posting Some Of The Hedge Fund World's Best Returns at Forbes
08:00AM  Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform PR Newswire
08:00AM  Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform CNW Group
Jan-17-15 09:00AM  Battered Hedge Fund Billionaire John Paulson Adds To Merger Bets at Forbes
Jan-16-15 08:02AM  These Top 10 Health Care Funds Are Full Of Vitality at Investor's Business Daily
Jan-15-15 07:24PM  Junk Bonds Show Pulse as Cash Dribbles Back in: Credit Markets at Bloomberg
05:26PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
05:00PM  Valeant Announces Redemption of All of the Approximately $500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 PR Newswire
05:00PM  Valeant Announces Redemption of All of the Approximately $500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 CNW Group
05:00PM  Valeant Announces Pricing Of Private Offering Of Senior Notes PR Newswire
05:00PM  Valeant Announces Pricing Of Private Offering Of Senior Notes CNW Group
02:12PM  3 Reasons To Be Bullish On Generic Drug Firm Akorn at Investor's Business Daily
10:30AM  Valeant Pharmaceuticals International -- Moody's revises Valeant outlook to positive, rates new notes B1 at Moody's
09:15AM  Valeant Announces Launch of Private Offering of Senior Notes PR Newswire
08:50AM  Why Valeant Pharmaceuticals (VRX) Isn't Done Growing Earnings Yet - Tale of the Tape Zacks
Jan-14-15 01:15PM  Golden parachutes are lead balloon for investors at Financial Times
Jan-13-15 05:02PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial EDGAR Online
12:46PM  Valeant CEO: Allegations about our business not true CNBC
12:23PM  ValueAct Capital exits position in Dresser-Rand Group Market Realist
10:23AM  ValueAct Capital adds new position in 21st Century Fox Market Realist
08:23AM  ValueAct lowers stake in Adobe Systems Market Realist
Jan-12-15 07:05PM  Extended-Release Drugs Get Extra Scrutiny in U.S. Quality Focus at Bloomberg
06:30PM  Hot Big Caps: Valeant, Illumina, Chipotle Break Out at Investor's Business Daily
04:23PM  ValueAct continues to trim position in Rockwell Collins Market Realist
02:23PM  ValueAct slightly ups its position in Valeant Pharmaceuticals Market Realist
01:52PM  Celgene Says Q4 Earnings Beat, Sees Currency Impact at Investor's Business Daily
12:23PM  ValueAct gets seat on Armstrong World Industries board Market Realist
10:23AM  ValueAct raises its position in Allison Transmission Holdings Market Realist
Jan-09-15 04:35PM  Barclays Raises Valeant Pharmaceuticals' Price Target Benzinga
02:23PM  Highlights of ValueAct Capitals activist positions Market Realist
02:05PM  Five Far-Reaching Activist Investor Trends to Watch in 2015 at TheStreet
Jan-08-15 05:04PM  Stocks Mark Best Day In 3 Weeks As Indexes Jump 1.8% at Investor's Business Daily +6.19%
04:27PM  Stocks Finish Firmly Higher; Valeant, SunPower, Cigna Rocket at Investor's Business Daily
02:53PM  Stocks Keep To High Ground; Chipotle Shows Strength at Investor's Business Daily
01:21PM  Indexes Hold Big Gains; IBD 50 Growth Names Lead The Way at Investor's Business Daily
10:23AM  Stock Market Surges; Nasdaq, S&P 500 Retake 50-Day Lines at Investor's Business Daily
10:13AM  Valeant Surges on Higher Profit Forecast, Outlook for More Deals at Bloomberg
09:00AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financ EDGAR Online
12:00AM  Skadden and Jones Day Top M&A Rankings: Business of Law at Bloomberg
Jan-07-15 04:00PM  Mid-cap fund that beats the Street CNBC
02:44PM  Kyle Bass plans legal action on pharma patents at Financial Times
07:05AM  Bill Ackman: Valeant could have raised bid for Allergan CNBC
12:00AM  Drug Buying Spree Still Bustling as Pfizer Leads Hunt at Bloomberg
Jan-06-15 06:17PM  Will Allergan Buy Help Actavis Extend Growth Streak? at Investor's Business Daily
10:15AM  Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference PR Newswire
10:15AM  Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference CNW Group
12:00AM  Love Him or Hate Him, Bill Ackman Now Runs the Worlds Top Hedge Fund Bloomberg
Jan-05-15 09:58PM  ValueAct takes swipe at MSCI as activists flex muscles at Financial Times
07:33PM  ValueAct Capital's Jeff Ubben Seeks Board Seats, Transparency At MSCI at Forbes
07:33PM  ValueAct Capital Seeks Board Seats, Transparency At Governance Specialist MSCI at Forbes
05:25PM  Amid turmoil at Raleigh's biggest pharma, Salix CEO retires at
Jan-04-15 12:13PM  Deal of the year: Allergan at Financial Times
Jan-02-15 10:31AM  Stocks Start New Year With Gains; Intel Jumps at Investor's Business Daily
Dec-31-14 10:17AM  Event-Driven Hedge Funds Flailed In 2014: WSJ at
Dec-29-14 05:27PM  Will 2015 Be Different For Big Cap Stocks? at Investor's Business Daily
07:18AM  Bullish on biotech CNBC
Dec-26-14 09:25AM  Big pharma cashes in as M&A fever sweeps sector at Financial Times
Dec-24-14 01:01PM  Are There Any Winners Left In The Biotech Space? Benzinga
07:32AM  Pulse of health care... many healthy returns CNBC
Dec-22-14 06:23PM  Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive at Investor's Business Daily
08:23AM  J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015 at TheStreet
Dec-21-14 08:56AM  Corporate Review: A year to remember at Financial Times
Dec-18-14 07:10PM  Ackman Accused of Insider Trading in Allergan Shareholder Suit at Bloomberg
12:00PM  9 Big Stocks That Doubled in 2014 at 24/7 Wall St.
Dec-16-14 06:11PM  Great Stocks: Valeant Pharmaceuticals Near Buy Point at Investor's Business Daily
Dec-15-14 04:30PM  Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance PR Newswire
04:30PM  Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance CNW Group
Dec-13-14 12:01AM  Nestlé Chief Paul Bulcke Takes a Global View at
Dec-11-14 11:43AM  Shire Updates on Pipeline at Research & Development Day Zacks
Dec-10-14 01:39PM  JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 Zacks
09:18AM  Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan at TheStreet
Dec-09-14 03:02PM  Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Benzinga
01:50PM  UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 Zacks
01:38PM  Where Could ValueAct Capital's New $1.5 Billion Go? Benzinga
11:55AM  Stock Market Today: Wall Street Drops; Conn's Down 40% at Investor's Business Daily
08:41AM  Valeant puts dealmaking on hold to focus on the bottom line at Fortune
07:52AM  Will Valeant Pharmaceuticals (VRX) Stock be Helped Today by New Strategy? at TheStreet
06:56AM  December 9 Premarket Briefing: 10 Things You Should Know TheStreet
Dec-08-14 06:18PM  Two Gauges That Point To Fund Buying In A Stock at Investor's Business Daily
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stolz Brian M.EVP, Administration and CHCOJan 22Option Exercise0.007,350095,934Jan 26 05:22 PM
Schiller Howard BradleyEVP, Chief Financial OfficerJan 05Option Exercise0.0045,0000318,714Jan 07 05:38 PM
Stolz Brian M.EVP, CHCO and AdministrationDec 23Option Exercise0.0015,426096,618Dec 24 10:31 AM
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM
Farmer Ronald HaroldDirectorNov 24Buy163.951,000163,95032,504Dec 01 05:25 PM
UBBEN JEFFREY WDirectorNov 24Buy142.25210,00029,872,50017,780,936Nov 26 04:11 PM
Stolz Brian M.EVP, Administration and CHCOOct 10Option Exercise0.003,675084,791Oct 14 02:51 PM
Schiller Howard BradleyEVP and CFOOct 03Option Exercise0.0022,5000285,500Oct 07 04:19 PM
Stolz Brian M.EVP, Administration and CHCOSep 30Option Exercise0.0023,030093,064Oct 02 03:52 PM
Stolz Brian M.EVP, CHCO and AdministrationAug 06Option Exercise0.0018,111079,431Aug 07 03:53 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Option Exercise6.4510,20365,80934,202Jun 24 04:37 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Sale121.7010,2031,241,67623,999Jun 24 04:37 PM
Mirovsky PavelPresident of Valeant EuropeJun 02Sale131.2510,0001,312,4860Jun 04 03:19 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Option Exercise6.4510,00064,50033,999May 14 04:29 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Sale130.0810,0001,300,83623,999May 14 04:29 PM
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM
Kornwasser LaizerEVP, Company Group ChairmanMar 21Buy134.972,481334,85953,582Mar 25 01:06 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Option Exercise6.455,00032,25028,999Mar 19 04:33 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Sale141.725,000708,60023,999Mar 19 04:33 PM
Schiller Howard BradleyEVP, CFOFeb 11Option Exercise0.0090,0000312,704Feb 12 03:51 PM
Weldon RyanEVP, Company Group ChairmanFeb 11Option Exercise0.0011,0000103,823Feb 12 04:43 PM
Stolz Brian M.EVP, Administration & CHCOFeb 11Option Exercise0.0014,700069,783Feb 12 04:08 PM
Kornwasser LaizerEVP, Company Group ChairmanFeb 11Option Exercise0.0045,000073,390Feb 12 03:34 PM
Provencio Norma AnnDirectorFeb 03Sale136.235,000681,158147,206Feb 04 06:15 PM